1 / 15

Drug-Device Combination Products Market | Coherent Market Insights

Read here the latest updates on the Drug-Device Combination Products Market<br> published by CMI team.<br>

adwaitcoherent
Download Presentation

Drug-Device Combination Products Market | Coherent Market Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Marketing Insights https://www.coherentmarketinsights.com/ Market Research & Business Consulting Services Covid-19 Impact Tracker

  2. DRUG-DEVICE COMBINATION PRODUCTS MARKET ANALYSIS Drug-Device Combination Products Market, By Product Type (Drug Eluting Stents (Coronary stent, Peripheral Vascular stents), Infusion pumps (Implantable, Ambulatory), Photosensitizers, Orthopedic combination products (Bone graft imlants + antibiotic loaded bone cements), Wound care combination products, Inhalers (Nebulizers, MDI, DPI), Transdermal patches, Others( Intraocular implants, drug eluting beads)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

  3. Global Drug-Device Combination Products Market: Drivers Increasing prevalence of chronic disorders is expected to propel growth of the global drug-device combination products market over the forecast period. For instance, according to the study, “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045. Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034. North America held dominant position in the global drug-device combination products market in 2019, accounting for 41.4% share in terms of value, followed by Europe and Asia Pacific, respectively

  4. Figure 1. Global Drug-Device Combination Products Market Share (%), by Value, by Region, 2019

  5. Global Drug-Device Combination Products Market: Restraints Drug-device combination products increase the risk of infections, which is expected to hinder growth of the market. Although stent infection is rare, it is associated with high morbidity and mortality. Drug eluting stents (DES) are associated with higher infection risk than bare metal stent (BMS), owing to their antiproliferative effects. Moreover, presence of stringent and non-specific regulatory pathway for approval of Drug-device combination products is also expected to limit the market growth. There are separate regulatory approval pathways for pharmaceutical products and medical devices in the U.S. Investigational new drug (IND) application process is suited for pharmaceutical products, whereas medical devices fall under the investigational device exemption (IDE) pathway.

  6. Drug-Device Combination Products Market Report Coverage

  7. Global Drug-Device Combination Products Market: Opportunities Adoption of cloud-based data management software in combination products is expected to offer lucrative growth opportunities for players in the global drug-device combination products market. For instance, in January 2020, Medtronic plc launched Efficio, a cloud-based data management software for use with the SynchroMed II intrathecal drug delivery system, for effective management of targeted drug delivery pump. Moreover, launch of generic combination products is also expected to aid in growth of the market. For instance, August 2019, Teva Pharmaceutical Industries Ltd. launched generic version of Mylan’s EpiPen for young children. The global drug-device combination products market was valued at US$ 115.0 Bn in 2019 and is forecast to reach a value of US$ 214.1 Bn by 2027 at a CAGR of 8.1% between 2020 and 2027.

  8. Figure 2. Global Drug-Device Combination Products Market Value (US$ Bn), and Y-o-Y Growth (%), 2019-2027

  9. Market Trends/Key Takeaways Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in October 2019, Becton, Dickinson and Company launched the BD Intevia 1mL two-step disposable auto-injector. The market is witnessing higher preference for nasal sprays over auto injectors. For instance, in October 2019, Bryn Pharma, LLC reported that patients prefer bi-dose epinephrine nasal spray over Epipen auto injector. The company presented the related data at the American Academy of Pediatrics (AAP) National Conference & Exhibition.

  10. Global Drug-Device Combination Products Market: Competitive Landscape Major players operating in the global drug-device combination products market include, Teva Pharmaceutical Industries Ltd., Becton, Dickinson and Company, Integer Holdings Corporation, Abbott Laboratories, Medtronic plc, Allergan, Inc., Alcon, Inc., Arrow International, Inc., Bausch & Lomb, Inc., Boston Scientific Corporation, ALK, SINOMED, Kaléo, Haselmeier, Flowonix Medical, Inc., CareFusion Corporation, and Covidien PLC.

  11. Global Drug-Device Combination Products Market: Key Developments Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in February 2020, Flowonix Medical, Inc. received the U.S. Food and Drug Administration approval for its Prometra II Programmable Pump System for use with intrathecal baclofen. Prometra II Pump utilizes a pressure-driven, valve-gated delivery mechanism to deliver boluses of medication into the intrathecal space. Major players in the market are focused on adopting partnership strategies to expand their product portfolio. For instance, in October 2019, Haselmeier, a manufacturer of self-injection devices, partnered with Stevanato Group, a producer of glass primary packaging based in Italy, for development, manufacturing, and supply of the axis-D pen-injector in the therapeutic area of diabetes care.

  12. Request Sample Report Request Customization Download PDF Brochure Talk to Analyst Referance: https://www.coherentmarketinsights.com/market-insight/drug-device-combination-products-market-3919

  13. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. What We Provide:Customized Market Research AnalysisIndustry Analysis ServicesBusiness Consulting ServicesLong Term Engagement ModelCountry Specific Analysis

  14. Contact Us Mr. Shah Coherent Market Insights Pvt. LTD.Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S.Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  15. Thank You Kindly Follow CMI Social Media Profiles for the latest Company Updates. Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related